	US 11,938,168 B2
	Ophthalmic compositions and methods of use therefor
Colin Green, Auckland (NZ); Carol Ann Greene, Auckland (NZ); and Trevor Sherwin, Auckland (NZ)
Assigned to Auckland Uniservices Limited, Auckland (NZ)
Filed by Auckland Uniservices Limited, Auckland (NZ)
Filed on Oct. 23, 2020, as Appl. No. 17/078,949.
Application 17/078,949 is a continuation of application No. 15/555,909, granted, now 10,842,850, previously published as PCT/NZ2016/050033, filed on Mar. 4, 2016.
Claims priority of application No. 705727 (NZ), filed on Mar. 5, 2015.
Prior Publication US 2022/0047676 A1, Feb. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/18 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); C07K 14/495 (2006.01)

CPC A61K 38/1841 (2013.01) [A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61K 2300/00 (2013.01); C07K 14/495 (2013.01)]

16 Claims

1. A kit comprising:

(i) a composition comprising a TGFβ3 polypeptide which comprises the amino acid sequence of SEQ ID NO:1 or which is at least 90% identical to the amino acid sequence of SEQ ID NO:1, and dexamethasone or derivative thereof or a related steroidal agent; and

(ii) one or more contact lenses, corneal inserts, corneal implants, or intrastromal rings;

wherein the kit is adapted to be used in:

(a) treating or preventing progression of a refractive error of an eye;

(b) treating or preventing progression of a condition associated with thinning or irregularity of a cornea; or

(c) treating or preventing progression of a corneal condition selected from the group consisting of: keratoconus, myopia, hyperopia, astigmatism, presbyopia, and stromal dystrophies;

and wherein use of the kit in any of (a), (b), or (c) does not result in scarring in the cornea or in the eye.